Nimble Science is a technology company.
Nimble Science has raised $2.0M across 1 funding round.
Nimble Science has raised $2.0M in total across 1 funding round.
Nimble Science is a biotechnology company developing the SIMBA capsule, an ingestible device for passive sampling of small intestine luminal fluid to generate multi-omic microbiome datasets.[1][2][4] It serves pharmaceutical, diagnostic, nutritional, and medical research industries by enabling at-home collection of previously inaccessible gut data, solving the problem of limited insights into small intestine microbiomes critical for disease detection, personalized medicine, and product innovation.[1][3][5] The platform offers an "as-a-service" model with data analytics, earning recognition as NutraIngredients-USA's 2024 Startup of the Year for advancing personalized microbiome interventions.[1][3]
Growth momentum includes clinical validation against gold-standard methods like naso-intestinal catheters, yielding 20 times higher bacterial DNA than endoscopy, two patent filings in bacteriology and digestive systems, and partnerships for North American trials since 2021.[1][4][5] With under $5M in funding across one round, Nimble operates from Calgary, Canada, focusing on scalable GI analytics.[4][7]
Nimble Science was founded in 2018 by Dr. Gang (Joseph) Wang, PhD (co-founder and CTO), and Dr. Sabina Bruehlmann, PhD (CEO), both University of Calgary doctorate recipients with expertise in gut microbiome research.[1][4] The idea emerged from Hippocrates' insight that "all disease begins in the gut," driving development of the SIMBA (Small Intestine MicroBiome Aspiration) capsule for non-invasive small intestine sampling to revolutionize disease detection and treatment.[4]
Early traction came via collaborations with University of Calgary's Division of Gastroenterology and Lallemand Health Solutions, launching clinical studies in 2021.[4] Support from UCeed, Innovate Calgary, Hunter Hub, and Creative Destruction Lab accelerated progress to clinical-stage trials and industry partnerships.[4] Pivotal moments include a 2024 NutraIngredients award and platform launch providing contextual data analysis.[1][3]
Nimble rides the gut microbiome revolution in precision medicine, where small intestine data—housing bioactive microbes influencing 70-80% of immunity and nutrient absorption—has been inaccessible without invasive procedures.[1][4][5] Timing aligns with surging demand for personalized GI interventions amid rising digestive disorders, microbiome therapeutics, and nutraceuticals, amplified by post-2020 focus on at-home diagnostics.[3][5]
Market forces favoring Nimble include scalability of non-invasive sampling over endoscopy, enabling faster pharma R&D and probiotic development, plus AI-driven omics analysis.[2][6] It influences the ecosystem by partnering with leaders (e.g., Lallemand), powering consortia therapeutics like MRM Health's CORAL, and shifting paradigms from plate-to-bedside GI care.[2][4]
Nimble Science is poised to dominate small intestine sampling with its validated SIMBA platform, expanding "as-a-service" to more pharma and nutraceutical trials while building its omics database.[1][5] Trends like AI-multiomics integration, microbiome drugs for Parkinson's and beyond, and at-home precision health will propel growth, potentially through Series A funding or acquisitions by GI giants.[2][7]
Its influence may evolve from R&D enabler to direct diagnostic tool, tying back to the core promise: unlocking gut data to prevent disease at its source.[4]
Nimble Science has raised $2.0M in total across 1 funding round.
Nimble Science's investors include Family Office, Framework Venture Partners, Intuit Ventures, Alumni Ventures, Bascom Ventures.
Nimble Science has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $2.0M Seed | Family Office, Framework Venture Partners, Intuit Ventures, Alumni Ventures, Bascom Ventures |